Celularity Inc. Stock price

Equities

CELU

US1511902041

Biotechnology & Medical Research

Delayed Nasdaq 03:55:28 2024-03-28 pm EDT 5-day change 1st Jan Change
5.23 USD +5.87% Intraday chart for Celularity Inc. -2.43% +111.40%
Sales 2021 21.34M Sales 2022 17.98M Capitalization 187M
Net income 2021 -100M Net income 2022 14M EV / Sales 2021 29.3 x
Net cash position 2021 6.1M Net Debt 2022 51.62M EV / Sales 2022 13.3 x
P/E ratio 2021
-3.43 x
P/E ratio 2022
14.3 x
Employees 225
Yield 2021 *
-
Yield 2022
-
Free-Float 49.05%
More Fundamentals * Assessed data
Dynamic Chart
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy MT
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP CI
Celularity to Execute Reverse Stock Split Next Week MT
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024 CI
Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing MT
Genting Berhad Engages in Discussions with Celularity Inc CI
Celularity Inc. announced that it has received $6 million in funding from Dragasac Limited CI
Celularity Inc. announced that it expects to receive $6 million in funding from Dragasac Limited CI
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products MT
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare CI
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited DJ
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors CI
More news
1 day-1.79%
1 week-9.69%
Current month+37.99%
1 month+19.32%
3 months+191.62%
6 months+111.74%
Current year+99.68%
More quotes
1 week
4.75
Extreme 4.75
5.77
1 month
3.50
Extreme 3.5
7.97
Current year
1.87
Extreme 1.87
7.97
1 year
1.59
Extreme 1.59
8.90
3 years
1.59
Extreme 1.59
134.00
5 years
1.59
Extreme 1.59
134.00
10 years
1.59
Extreme 1.59
134.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 15-12-31
Director of Finance/CFO 54 21-07-15
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 64 21-07-15
Director/Board Member 67 17-12-31
Director/Board Member 62 17-06-30
More insiders
Date Price Change Volume
24-03-28 5.23 +5.87% 46 655
24-03-27 4.94 -1.79% 32,549
24-03-26 5.03 -4.55% 66,394
24-03-25 5.27 +1.54% 55,006
24-03-22 5.19 -3.17% 67,870

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn's disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock Celularity Inc. - Nasdaq